3. Symdeko by Arlene Weintraub Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.
AbbVie buys Galapagos’ cystic fibrosis assets despite weak data by Nick Paul Taylor Thursday, October 25, 2018 The deal follows two underwhelming clinical trial readouts that suggested the drugs may struggle to compete with Vertex.
New tactics against antibiotic-resistant infections by Arlene Weintraub Thursday, September 27, 2018 Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.
Boehringer lands option on cystic fibrosis gene therapy by Nick Paul Taylor Monday, August 6, 2018 Boehringer will work with British academics and Oxford BioMedica to develop an inhaled, lentiviral vector-based gene therapy for cystic fibrosis.
Celtaxsys’ cystic fibrosis drug reduces exacerbations in phase 2 by Conor Hale Thursday, August 2, 2018 Celtaxsys’ cystic fibrosis drug cleared phase 2 by reducing lung exacerbations, such as heavy coughing episodes that can lead to irreversible damage.
Lung cell discovery opens new route for cystic fibrosis treatment by Angus Liu Wednesday, August 1, 2018 A rare cell type, discovered by two teams and named as "pulmonary ionocyte," appears to help drive cystic fibrosis.
AbbVie dumps Galapagos’ cystic fibrosis combo by Nick Paul Taylor Friday, June 29, 2018 The action prompted Galapagos to review the future of its relationship with AbbVie—and provided a boost to cystic fibrosis rival Vertex.
Vertex doubles size of cystic fibrosis drug discovery site by Nick Paul Taylor Tuesday, June 19, 2018 Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.
Translate files for $115M IPO to trial mRNA cystic fibrosis drug by Nick Paul Taylor Monday, June 4, 2018 The IPO will tee Translate up to trial an mRNA candidate designed to enable all cystic fibrosis patients to produce fully functional CTFR proteins.
FDA has dosing questions for Vertex’s Kalydeco follow-up by Phil Taylor Friday, April 27, 2018 Vertex says its long-acting version of Kalydeco has been held up by an FDA data request—but analysts think it could be a bigger issue for its rivals.
